


EVIDENCE THAT EMPOWERS CHANGE

Empowering decision-making in patients with advanced CSCC and advanced BCC



Patient portrayal.



ADVANCED CSCC: LIBTAYO is the **FIRST** treatment indicated for patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.¹



ADVANCED BCC: LIBTAYO is the **FIRST AND ONLY** treatment indicated for patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.¹



*Estimate based on IQVIA medical claims data from October 2018 through May 2023 and calibrated with actual vials sold.²
IO=immunotherapy.



[†]FDA approved in advanced CSCC in 2018. Includes clinical trial experience and postmarketing data.^{1,3}



[‡]Since its first approval in 2018.¹ Estimate based on IQVIA medical claims data from October 2018 through May 2023 and calibrated with actual vials sold.²


Important Safety Information

Warnings and Precautions

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue at any time after starting treatment. While immune-mediated adverse reactions usually occur during treatment, they can also occur after discontinuation. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. Early identification and management are essential to ensuring safe use of PD-1/PD-L1-blocking antibodies. The definition of immune-mediated adverse reactions included the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Monitor closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions.


Please see additional Important Safety Information throughout and accompanying full Prescribing Information.




Advanced CSCC and advanced BCC can be complex and may lead to poor prognosis⁴⁻⁶

Every year in the United States,

~40,000 patients progress to aCSCC⁷ **>20,000** patients progress to aBCC^{8,9}



aCSCC and aBCC may have psychosocial and functional impact on patients^{5,10-13}




aBCC=advanced BCC; aCSCC=advanced CSCC.

Early patient identification and a multidisciplinary treatment approach are vital for improving aCSCC and aBCC outcomes^{5,14-17}

Collaboration among different specialists is recommended to discuss the appropriate course of action for patients with certain characteristics¹⁶⁻¹⁹:

- Reradiation
- Unresectable or inoperable disease
- Invasion of surrounding tissue
- Multiple recurrences
- Residual disease after multiple surgeries
- Lack of response to systemic treatment
- Intolerance to systemic treatment
- Disease progression on systemic treatment

Guidelines unanimously recommend working with a multidisciplinary team (eg, dermatologists, oncologists, and surgeons) for treating patients with aCSCC and aBCC¹⁶⁻²⁰



NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to [NCCN.org](https://www.nccn.org).


NCCN=National Comprehensive Cancer Network® (NCCN®).
NCCN is a registered trademark of the National Comprehensive Cancer Network® (NCCN®).

Consult and comanage with a multidisciplinary team to consider all appropriate treatment options for your patients with aCSCC and aBCC

aCSCC patients can benefit from a multidisciplinary approach¹⁶

Surgery and radiation are important treatment options but may not be appropriate for some patients with aCSCC^{16,21-25}


Surgery may result in severe disfigurement or dysfunction in anatomically challenging locations, and radiation may cause acute and late toxicities^{16,21,22}



PD-1 inhibitor therapy could be a treatment option for your patients if surgery and RT are ruled out³⁶


aBCC patients can benefit from a multidisciplinary approach¹⁷

HHIs are an important step in the aBCC treatment algorithm, but many patients discontinue or are inappropriate for HHI therapy²⁶⁻³⁶



PD-1 inhibitor therapy could be an appropriate next step if HHIs are deemed inappropriate or permanently discontinued³⁶

LIBTAYO® (cemiplimab-rwlc) can help activate your patient's immune system to recognize, attack, and kill the cancer cells that have found ways to avoid the immune system¹



Tumor immune evasion

T-cell inactivation can result from interaction of the PD-1 receptor on tumor-infiltrating T cells with its ligands, PD-L1 and PD-L2, expressed on tumor cells.

T-cell activity restored

LIBTAYO binds to PD-1 on T cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells, helping to restore the antitumor T-cell response.

LIBTAYO is a PD-1 inhibitor, not chemotherapy or radiation therapy

PD-L1=programmed death-ligand 1; PD-L2=programmed death-ligand 2.

Important Safety Information (continued)
Warnings and Precautions (continued)
Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue LIBTAYO depending on severity of the adverse reaction (see Section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if LIBTAYO requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

Cemiplimab-rwlc (LIBTAYO®) is an immunotherapy administered by oncologists and is recommended by national guidelines^{1,18,19}

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.1.2024 recommend cemiplimab-rwlc (LIBTAYO®) as a preferred systemic therapy option for appropriate patients with advanced CSCC^{18*}

NCCN Category 2A* preferred recommendation			
NCCN RECOMMENDED CATEGORY 2A* OPTION FOR ADVANCED CSCC	Locally advanced CSCC	Regional CSCC	Distant metastatic CSCC or regionally recurrent CSCC‡
	When curative surgery and curative radiation therapy are not feasible†	When curative surgery and curative radiation therapy are not feasible	When curative surgery and curative radiation therapy are not feasible
	A preferred PD-1 inhibitor	A preferred PD-1 inhibitor	A preferred PD-1 inhibitor

NCCN Guidelines® for Basal Cell Skin Cancer V.3.2024 include cemiplimab-rwlc (LIBTAYO®) as a recommended systemic therapy option for appropriate patients with advanced BCC^{19*}

NCCN Category 2A* recommended systemic therapy option		
NCCN RECOMMENDED CATEGORY 2A* OPTION FOR ADVANCED BCC	Locally advanced BCC§	Nodal or distant metastatic BCC
	For patients previously treated with an HHI or for whom an HHI is not appropriate	For patients previously treated with an HHI or for whom an HHI is not appropriate
	Only recommended PD-1 inhibitor for appropriate patients with advanced BCC	


NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to NCCN.org.

NCCN=National Comprehensive Cancer Network® (NCCN®).
NCCN is a registered trademark of the National Comprehensive Cancer Network® (NCCN®).


*Category 2A recommendation is based upon lower-level evidence; there is uniform NCCN consensus that the intervention is appropriate. All recommendations are Category 2A unless otherwise specified.^{18,19}
†If curative surgery and curative RT are not feasible, recommend multidisciplinary consultation to consider systemic therapy alone. Assessment of feasibility of radiation therapy should be made by a radiation oncologist.¹⁸
‡For complicated cases, consider multidisciplinary consultation.¹⁸
§Locally advanced disease is defined by those that have primary or recurrent extensive disease where surgery and/or radiation therapy may not result in a cure or would possibly produce a significant functional limitation.¹⁹



Situations where LIBTAYO® (cemiplimab-rwlc) may be appropriate for patients with aCSCC and aBCC¹



aCSCC: LIBTAYO is the **FIRST** treatment indicated for patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.¹



aBCC: LIBTAYO is the **FIRST AND ONLY** treatment indicated for patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.¹

When surgery may not be appropriate for aCSCC and aBCC^{2,16,19*}

Locally invasive disease: Tumor extending into the underlying tissue, cartilage, bone, or nerve	Recurrence: Recurrence at the same site after 2 or more surgical procedures	Anticipation of substantial morbidity or deformity from surgery
Anatomically challenging location of disease: <ul style="list-style-type: none">• Periorbital lesions threatening the eye• Nasal or auricular lesions requiring rhinectomy or auriclectomy		Other: <ul style="list-style-type: none">• Patient refusal of surgery• Other conditions deemed contraindicating for surgery

When RT may not be appropriate for aCSCC and aBCC^{2,16,19*}

Anatomically challenging location of disease: Locations for which RT would be associated with unacceptable toxicity risk	Prior treatment: Further RT would exceed the threshold of acceptable cumulative dose	Other: <ul style="list-style-type: none">• Patient refusal of RT• Clinical judgment that tumor would be unlikely to respond to RT• Other conditions deemed contraindicating for RT
--	--	---

When HHIs may not be appropriate for aBCC^{2,26-36*}

Prior progression of disease on HHIs Based on clinician judgement	Intolerable HHI-related adverse events
---	---

*Assessment by individual physician or surgeon may vary.


Important Safety Information (continued)
Warnings and Precautions (continued)
Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroids. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below. The incidence and severity of immune-mediated adverse reactions were similar when LIBTAYO was administered as a single agent or in combination with chemotherapy.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

LIBTAYO was validated in the largest prospective clinical trial for advanced CSCC^{1,37-45}

Study 1540 was a global, pivotal, open-label, nonrandomized, multicohort study in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation¹



Study 1540—EMPOWER-CSCC 1—was a global, pivotal, open-label, nonrandomized, multicohort study that included 193 patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation (targeted enrollment). Patients received LIBTAYO 3 mg/kg intravenously every 2 weeks for up to 96 weeks or LIBTAYO 350 mg every 3 weeks for up to 54 weeks. Treatment continued until progression of disease, unacceptable toxicity, or completion of planned treatment.¹

Study 1540 excluded patients with autoimmune disease who required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior treatment with anti-PD-1/PD-L1-blocking antibodies or other immune checkpoint inhibitor therapy; infection with HIV, hepatitis B, or hepatitis C; or ECOG PS ≥ 2 .¹

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.¹

In Study 1540, 66% of patients received LIBTAYO as first-line systemic therapy, 81% had received prior cancer-related surgery, and 68% had received any prior radiotherapy. Of patients with mCSCC, 23% had only nodal metastases and 77% had distant metastases. No PD-L1 testing is required before starting LIBTAYO for advanced CSCC.^{1,46}

CR=complete response; DOR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; ICR=independent central review; ORR=objective response rate; Q2W=every 2 weeks; Q3W=every 3 weeks.

Important Safety Information (continued)
Warnings and Precautions (continued)
Severe and Fatal Immune-Mediated Adverse Reactions (continued)


Immune-mediated pneumonitis: LIBTAYO can cause immune-mediated pneumonitis. In patients treated with other PD-1/PD-L1-blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 2.6% (33/1281) of patients receiving LIBTAYO, including Grade 4 (0.3%), Grade 3 (0.6%), and Grade 2 (1.6%). Pneumonitis led to permanent discontinuation in 1.3% of patients and withholding of LIBTAYO in 1.4% of patients.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



LIBTAYO® (cemiplimab-rwlc) is a proven treatment choice in advanced CSCC¹

Efficacy results of Study 1540 for patients with mCSCC or laCSCC who were not candidates for curative surgery or radiation^{1*}



The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.¹

ORR was determined by the proportion of patients with best overall response of CR or PR based on ICR evaluation, as determined by RECIST version 1.1 for radiologic assessments, or by modified WHO Criteria for photographic assessments, or by the composite response criteria for patients assessed by both radiology and photography.²

PR was defined as a decrease of ≥30% in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, per RECIST 1.1. PR of externally visible disease was defined as a decrease of ≥50% in the sum of products of perpendicular longest diameters of target lesions, per WHO Criteria. Nontarget lesions could not have PD, and there could be no new lesions. Responses had to be maintained for at least 4 weeks.²

CR was defined as a disappearance of all target lesions for at least 4 weeks. Nontarget lesions also had to show a CR, and there could be no new lesions. Any pathological lymph nodes (whether target or nontarget) must have shown a reduction in short axis to <10 mm (<1 cm). Only includes patients with complete healing of prior cutaneous involvement; patients with laCSCC in Study 1540 required biopsy to confirm a CR.²

*Data cutoff was March 2022.⁴⁷
CI=confidence interval; PD=progressive disease; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; WHO=World Health Organization.

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)


Immune-mediated pneumonitis (continued): Systemic corticosteroids were required in all patients with pneumonitis. Pneumonitis resolved in 61% of the 33 patients. Of the 18 patients in whom LIBTAYO was withheld, 10 reinitiated after symptom improvement; of these, 4/10 (40%) had recurrence of pneumonitis.

Immune-mediated colitis: LIBTAYO can cause immune-mediated colitis. The primary component of immune-mediated colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1-blocking antibodies. In cases of corticosteroid-refractory immune-mediated colitis, consider repeating infectious workup to exclude alternative etiologies.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

LIBTAYO demonstrated clinically meaningful and durable responses in advanced CSCC^{1*}

Median DOR in Study 1540



Median TTR was rapid at 2.1 months (range, 1.7 to 22.8 months) for all cohorts combined, based on an open-label, single-arm trial that did not include comparisons to other treatments^{1,2†}

*Data cutoff was March 2022.⁴⁷
†First assessment was performed at 8 weeks.²
TTR=time to response.

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated colitis (continued): Immune-mediated colitis occurred in 2% (25/1281) of patients receiving LIBTAYO, including Grade 3 (0.8%) and Grade 2 (0.9%). Colitis led to permanent discontinuation in 0.4% of patients and withholding of LIBTAYO in 1.2% of patients. Systemic corticosteroids were required in all patients with colitis. Colitis resolved in 56% of the 25 patients. Of the 16 patients in whom LIBTAYO was withheld, 6 reinitiated LIBTAYO after symptom improvement; of these, 4/6 (67%) had recurrence

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.




LIBTAYO® (cemiplimab-rwlc) over time: Continued efficacy demonstrated across data readouts in Study 1540^{1,2*}

Response rates over time in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation^{1,2}

The following data represent 5 years of follow-up for Group 1 and 4 years of follow-up for Group 2 and Group 3. Follow-ups for each group are based on time from primary analysis.^{1,2}

Median duration of follow-up: mCSCC 3 mg/kg Q2W—18.5 months (range, 1.1–41.0); laCSCC 3 mg/kg Q2W—15.5 months (range, 0.8–43.2); mCSCC 350 mg Q3W—17.3 months (range, 0.6–43.4).^{1,2}



Durable responses demonstrated across data readouts^{1,6,46,48–50*}

Median DOR¹



*Response rates and duration of response are based on analysis by ICR of Study 1540 at time of data cutoff: March 2022.^{1,2,47}

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)


Immune-mediated hepatitis: LIBTAYO can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 2.4% (31/1281) of patients receiving LIBTAYO, including fatal (<0.1%), Grade 4 (0.3%), Grade 3 (1.6%), and Grade 2 (0.2%). Hepatitis led to permanent discontinuation of LIBTAYO in 1.4% of patients and withholding of LIBTAYO in 0.7% of patients. Systemic corticosteroids were required in all patients with hepatitis. Additional immunosuppression with mycophenolate was required in 13% (4/31) of these patients. Hepatitis resolved in 39% of the 31 patients. Of the 9 patients in whom LIBTAYO was withheld, 5 reinitiated LIBTAYO after symptom improvement; of these, 1/5 (20%) had recurrence.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

LIBTAYO delivered clinically meaningful responses in all cohorts combined^{1,2,46–49*}

Response rates over time (N=193)^{1,46,48,49}

Median duration of follow-up: 15.7 months (range, 0.6–43.2).^{1,2}



With each of these data readouts, LIBTAYO continued to demonstrate durable responses in patients with advanced CSCC^{1,2}

Among responders, median time to CR^{51†} 11.2 months (IQR, 7.4–14.8; n=31)

Median DOR^{1*}



*Response rates and duration of response are based on analysis by ICR of Study 1540 at time of data cutoff: March 2022.^{1,2,47}

[†]Combined median ORR for 2018 is derived from 115 patients in Groups 1 and 3.⁴⁸

[‡]Median time to CR is derived from 31 complete responders. No firm conclusions can be drawn because results are from an aggregation of additional, pooled, long-term data from the original study groups of the phase 2, open-label, non-randomized, multicenter study.⁵¹ IQR=interquartile range.

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies:

• **Adrenal insufficiency:** LIBTAYO can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold LIBTAYO depending on severity. Adrenal insufficiency occurred in 0.5% (6/1281) of patients receiving LIBTAYO, including Grade 3 (0.5%). Adrenal insufficiency led to permanent discontinuation of LIBTAYO in 1 (<0.1%) patient. LIBTAYO was withheld in 1 (<0.1%) patient due to adrenal insufficiency and not reinitiated. Systemic corticosteroids were required in 83% (5/6) patients with adrenal insufficiency; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency had resolved in 17% of the 6 patients.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



Meaningful tumor reduction in clinical trial patients with mCSCC²

85-year-old male with mCSCC; supraclavicular lesion with distant metastasis^{2*}

Supra-clavicular Lesion



Individual patient responses may vary. This is an example from the 30% of patients who had a PR in the combined analysis of patients who received LIBTAYO® (cemiplimab-rwlc) in Study 1540.¹

The duration of response for this patient was 36.57+ months. At data cutoff, he had completed his treatment per protocol, and was in his 16th month of posttreatment follow-up. At this time, his response was still ongoing.²



Actual clinical trial patient.

Clinical outcomes (as of data cutoff March 2022)^{2,47}

- **Best overall response:** PR per composite (RECIST 1.1 + WHO Criteria) evaluation by ICR
 - **Time to response:** 8 weeks (1.74 months)
 - **Duration of response:** 36.57+ months
- Plus sign (+) denotes ongoing at last assessment.¹
- *Patient received LIBTAYO 3 mg/kg every 2 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.²

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies (continued):

- **Hypophysitis:** LIBTAYO can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue depending on severity. Hypophysitis occurred in 0.5% (7/1281) of patients receiving LIBTAYO, including Grade 3 (0.2%) and Grade 2 (0.3%) adverse reactions. Hypophysitis led to permanent discontinuation of LIBTAYO in 1 (<0.1%) patient and withholding of LIBTAYO in 2 (0.2%) patients. Systemic corticosteroids were required in 86% (6/7) of patients with hypophysitis. Hypophysitis resolved in 14% of the 7 patients. Of the 2 patients in whom LIBTAYO was withheld for hypophysitis, none of the patients reinitiated

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

Meaningful tumor reduction in clinical trial patients with laCSCC²

57-year-old male with laCSCC who was not a candidate for curative surgery or curative radiation. Patient pictured suffered from a lesion in which the clinical judgment was that the tumor would be unlikely to respond to RT^{2*}

Interior Auricular Lesion



Individual patient responses may vary. This is an example from the 30% of patients who had a PR in the combined analysis of patients who received LIBTAYO in Study 1540.¹

The duration of response for this patient was 20.5 months. At data cutoff, he had completed his treatment per protocol, and was in his 3rd month of posttreatment follow-up. At this time, he was no longer in response due to having progressive disease.²



Actual clinical trial patient.

Clinical outcomes (as of data cutoff March 2022)^{2,47}

- **Best overall response:** PR per composite (RECIST 1.1 + WHO Criteria) evaluation by ICR
 - **Time to response:** 24 weeks (5.55 months)
 - **Duration of response:** 20.5 months
- *Patient received LIBTAYO 3 mg/kg every 2 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.²

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies (continued):

- **Thyroid disorders:** LIBTAYO can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue LIBTAYO depending on severity
- **Thyroiditis:** Thyroiditis occurred in 0.6% (8/1281) of patients receiving LIBTAYO, including Grade 2 (0.3%) adverse reactions. No patient discontinued LIBTAYO due to thyroiditis. Thyroiditis led to withholding of LIBTAYO in 1 (<0.1%) patient. Systemic corticosteroids were not required in any patient with thyroiditis. Thyroiditis resolved in 13% of the 8 patients. Blood thyroid stimulating hormone increased and blood thyroid stimulating hormone decreased have also been reported

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



Meaningful tumor reduction in clinical trial patients with mCSCC²

66-year-old male with mCSCC who was not a candidate for curative surgery or curative radiation. Patient pictured suffered from numerous periclavicular lesions^{2*}

Numerous Periclavicular Lesions



Individual patient responses may vary. This is an example from the **17%** of patients who had a **CR** in the combined analysis of patients who received LIBTAYO® (cemiplimab-rwlc) in Study 1540.¹

The duration of response for this patient was 31.08+ months. At data cutoff, he had completed his treatment per protocol. At that time, his response was still ongoing.^{2,47}



Actual clinical trial patient.

Clinical outcomes (as of data cutoff March 2022)^{2,47}

- **Best overall response:** CR per composite (RECIST 1.1 + WHO Criteria) evaluation by ICR
- **Time to response:** 24 weeks (5.55 months)
- **Duration of response:** 31.08+ months

Plus sign (+) denotes ongoing at last assessment.¹

*Patient received LIBTAYO 3 mg/kg every 2 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.²

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies (continued):

- **Hyperthyroidism:** Hyperthyroidism occurred in 3% (39/1281) of patients receiving LIBTAYO, including Grade 3 (<0.1%) and Grade 2 (0.9%). No patient discontinued treatment and LIBTAYO was withheld in 7 (0.5%) patients due to hyperthyroidism. Systemic corticosteroids were required in 8% (3/39) of patients. Hyperthyroidism resolved in 56% of 39 patients. Of the 7 patients in whom LIBTAYO was withheld for hyperthyroidism, 2 patients reinitiated LIBTAYO after symptom improvement; of these, none had recurrence of hyperthyroidism

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

Meaningful tumor reduction in clinical trial patients with laCSCC²


70-year-old male with laCSCC who was not a candidate for curative surgery or curative radiation. Patient pictured suffered from invasive disease and radiotherapy was contraindicated^{2*}

Cranial Lesion



Individual patient responses may vary. This is an example from the **30%** of patients who had a **PR** in the combined analysis of patients who received LIBTAYO in Study 1540.¹

The duration of response for this patient was 28.81 months. At data cutoff, he had completed his treatment per protocol, and was in his 9th month of posttreatment follow-up. At this time, he was no longer in response due to having progressive disease.²



Actual clinical trial patient.

Clinical outcomes (as of data cutoff March 2022)^{2,47}

- **Best overall response:** PR per composite (RECIST 1.1 + WHO Criteria) evaluation by ICR
- **Time to response:** 16 weeks (3.71 months)
- **Duration of response:** 28.81 months

*Patient received LIBTAYO 3 mg/kg every 2 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.²

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies (continued):

- **Hypothyroidism:** Hypothyroidism occurred in 7% (87/1281) of patients receiving LIBTAYO, including Grade 3 (<0.1%) and Grade 2 (6%). Hypothyroidism led to permanent discontinuation of LIBTAYO in 3 (0.2%) patients. Hypothyroidism led to withholding of LIBTAYO in 9 (0.7%) patients. Systemic corticosteroids were required in 1.1% (1/87) of patients with hypothyroidism. Hypothyroidism resolved in 6% of the 87 patients. Majority of the patients with hypothyroidism required long-term thyroid hormone replacement. Of the 9 patients in whom LIBTAYO was withheld for hypothyroidism, 1 reinitiated LIBTAYO after symptom improvement and did not have recurrence of hypothyroidism

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



LIBTAYO® (cemiplimab-rwlc) demonstrated a favorable safety profile in patients with advanced CSCC in Study 1540¹

Adverse reactions (ARs) in ≥10% of patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation, and who received LIBTAYO in Study 1540¹

Adverse reactions	Advanced CSCC (N=358)	
	All grades, %	Grades 3–4, %
General disorders and administration site		
Fatigue*	38	2.2
Skin and subcutaneous tissue		
Rash [†]	34	1.7
Pruritus [‡]	22	0.3
Actinic keratosis	10	0
Musculoskeletal and connective tissue		
Musculoskeletal pain [§]	33	2.5
Gastrointestinal		
Diarrhea	26	1.1
Nausea	21	0
Constipation	13	0.3
Vomiting [¶]	11	0.6
Infections and infestations		
Upper respiratory tract infection [#]	14	1.1
Skin infection**	11	4.5
Respiratory		
Cough ^{††}	12	0
Metabolism and nutrition		
Decreased appetite	11	0.6
Nervous system disorders		
Headache ^{‡‡}	10	0
Dizziness ^{§§}	10	0.3

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03.¹

*Fatigue is a composite term that includes fatigue and asthenia.¹

[†]Rash is a composite term that includes rash, rash maculopapular, dermatitis, erythema, eczema, dermatitis bullous, rash erythematous, dermatitis acneiform, psoriasis, dermatitis contact, blister, pemphigoid, rash papular, hand dermatitis, skin exfoliation, autoimmune dermatitis, rash pruritic, rash macular, rash pustular, urticaria, dermatitis atopic, drug eruption, eczema asteatotic, skin reaction, dermatitis psoriasiform, eczema nummular, exfoliative rash, and immune-mediated dermatitis.¹

[‡]Pruritus is a composite term that includes pruritus and pruritus allergic.¹

[§]Musculoskeletal pain is a composite term that includes arthralgia, back pain, myalgia, polyarthrits, pain in extremity, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, bone pain, immune-mediated arthritis, and spinal pain.¹

^{||}Diarrhea is a composite term that includes diarrhea, colitis, and autoimmune colitis.¹

[¶]Vomiting is a composite term that includes hematemesis and vomiting.¹

[#]Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, nasopharyngitis, sinusitis, influenza-like illness, rhinitis, influenza, viral upper respiratory tract infection, respiratory tract infection, influenza A virus test positive, and pharyngitis.¹

^{**}Skin infection is a composite term that includes skin infection, cellulitis, fungal skin infection, and staphylococcal skin infection.¹

^{††}Cough is a composite term that includes cough, productive cough, and upper airway cough syndrome.¹

^{‡‡}Headache is a composite term that includes headache, sinus headache, and migraine.¹

^{§§}Dizziness is a composite term that includes dizziness, vertigo, vertigo positional, and dizziness postural.¹

In 26 patients with advanced CSCC treated with LIBTAYO in Study 1423, safety data were consistent with those described above from Study 1540.¹

Warnings and Precautions for LIBTAYO¹

Warnings and Precautions for LIBTAYO include severe and fatal immune-mediated adverse reactions such as immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic HSCT; and embryo-fetal toxicity. Monitor for symptoms and signs of immune-mediated adverse reactions.

For more information on Warnings and Precautions, see additional Important Safety Information throughout and in Section 5 of the accompanying full Prescribing Information.

Grade 3 or 4 laboratory abnormalities in patients with advanced CSCC in Study 1540¹

Grade 3 or 4 laboratory abnormalities worsening from baseline in ≥1% of patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation and who received LIBTAYO

Laboratory abnormality	Advanced CSCC (N=358)
	Grades 3–4, %*
Hematology	
Lymphopenia	7.0
Anemia	4.1
Electrolytes	
Hyponatremia	4.9
Hypophosphatemia	4.1
Hypercalcemia	2.0
Hypokalemia	1.5
Coagulation	
Increased INR	2.9
Chemistry	
Increased aspartate aminotransferase	1.5
Hypoalbuminemia	1.2

- The most common (≥20%) ARs were fatigue, rash, musculoskeletal pain, diarrhea, pruritus, and nausea¹
- The most common Grade 3 or 4 ARs (≥2%) were hypertension, skin infection, pneumonia, anemia, fatigue, musculoskeletal pain, and pneumonitis. The most common (≥4%) Grade 3 or 4 laboratory abnormalities worsening from baseline were lymphopenia, hyponatremia, anemia, and hypophosphatemia¹
- Serious ARs occurred in 41% of patients¹
- Serious ARs that occurred in at least 2% of patients were pneumonia (3.6%), skin infection (3.6%), and pneumonitis (2.8%)¹
- Fatal ARs occurred in 5% of patients who received LIBTAYO, including deaths due to infections (2.2%)¹
- LIBTAYO was permanently discontinued due to ARs in 12% of patients¹
- ARs resulting in permanent discontinuation in at least 2 patients were pneumonitis, rash, confusional state, general physical health deterioration, hemorrhage, liver function test abnormalities, and musculoskeletal pain¹
- Dosage interruptions of LIBTAYO due to an AR occurred in 36% of patients. ARs which required dosage interruption in ≥2% of patients included diarrhea, infusion-related reaction, upper respiratory tract infection, liver function test abnormalities, musculoskeletal pain, pneumonitis, and rash¹

Toxicity graded per NCI CTCAE v.4.03.¹

*Percentages are based on the number of patients with at least 1 postbaseline value available for that parameter.¹

INR=international normalized ratio.

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated endocrinopathies (continued):


- **Type 1 diabetes mellitus, which can present with diabetic ketoacidosis:**
Monitor for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold LIBTAYO depending on severity. Type 1 diabetes mellitus occurred in <0.1% (1/1281) of patients (Grade 4). No patient discontinued treatment due to Type 1 diabetes mellitus. Type 1 diabetes mellitus led to withholding of LIBTAYO in 0.1% of patients, treatment was reinitiated after symptom improvement. Patient received long-term insulin therapy

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



In patients with advanced BCC previously treated with an HHI, **LIBTAYO® (cemiplimab-rwlc) was validated in the largest prospective clinical trial for a PD-1 inhibitor¹**

Study 1620 trial design¹



Primary endpoint¹:

- Confirmed ORR as assessed by ICR

Secondary endpoints included²:

- DOR
- CR rate
- Safety and tolerability

Study 1620 was an open-label, multicenter, phase 2, nonrandomized study that included 138 patients with laBCC or mBCC who had progressed on HHI therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant of prior HHI therapy. Treatment continued until progression of disease, unacceptable toxicity, or completion of planned treatment.^{1,2}

Study 1620 excluded patients with autoimmune disease that required systemic therapy with immunosuppressant agents within 5 years; history of solid organ transplant; prior treatment with anti-PD-1/PD-L1 therapy or other immune checkpoint inhibitor therapy; infection with HIV, hepatitis B, or hepatitis C; or ECOG PS ≥ 2 .¹

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated nephritis with renal dysfunction: LIBTAYO can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.7% (9/1281) of patients receiving LIBTAYO, including fatal (<0.1%), Grade 3 (<0.1%), and Grade 2 (0.5%). Nephritis led to permanent discontinuation in 0.2% of patients and withholding of LIBTAYO in 0.4% of patients. Systemic corticosteroids were required in all patients with nephritis. Nephritis resolved in 78% of the 9 patients. Of the 5 patients in whom LIBTAYO was withheld, 4 reinitiated LIBTAYO after symptom improvement; of these, 1/4 (25%) had recurrence.


Immune-mediated dermatologic adverse reactions: LIBTAYO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) has occurred with PD-1/PD-L1-blocking antibodies. Immune-mediated dermatologic adverse reactions occurred in 1.9% (24/1281) of patients receiving LIBTAYO, including Grade 3 (0.9%) and Grade 2 (0.8%).

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).


Proven and durable responses in both laBCC and mBCC¹

In patients with laBCC previously treated with an HHI¹

32% ORR* (95% CI, 22%–43%)




- Median duration of follow-up was 15.9 months (range, 0.5–39.7)^{1,2}




In patients with mBCC previously treated with an HHI¹

22% ORR* (95% CI, 12%–36%)



- Median duration of follow-up was 8.4 months (range, 1.5–36.2)^{1,2}



Median TTR was 4.3 months (range, 2.1–21.4 months) for laBCC and 3.1 months (range, 2.0–10.5 months) for mBCC.¹

At the 1-year post-primary analysis data readout^{1,2},

- Percentage of patients with laBCC responding to LIBTAYO (ORR) increased from 29% at primary analysis to 32%
- Median DOR had not been reached for patients with laBCC who responded to LIBTAYO

ORR was determined by the proportion of patients with best overall response of CR or PR based on ICR evaluation, as determined by RECIST version 1.1 for radiologic assessments, or by modified WHO Criteria for photographic assessments, or by the composite response criteria for patients assessed by both radiology and photography.²

CR was defined as a disappearance of all target lesions for at least 4 weeks. Nontarget lesions also had to be a CR and there could be no new lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to <10 mm (<1 cm). Only includes patients with complete healing of prior cutaneous involvement; patients with laBCC in the study required biopsy to confirm CR.²

PR was defined as a decrease of $\geq 30\%$ in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters, per RECIST 1.1. PR of externally visible disease is defined as a decrease of $\geq 50\%$ in the sum of products of perpendicular longest diameters of target lesions per WHO Criteria. Nontarget lesions could not have PD, and there could be no new lesions. Responses had to be maintained for at least 4 weeks.²

*Data cutoff was May 2021.²

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Immune-mediated dermatologic adverse reactions (continued):

Immune-mediated dermatologic adverse reactions led to permanent discontinuation in 0.2% of patients and withholding of LIBTAYO in 1.3% of patients. Systemic corticosteroids were required in all patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% of the 24 patients.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).



In a study of patients with laBCC previously treated with an HHI,
Clinically meaningful tumor reduction observed after treatment with LIBTAYO® (cemiplimab-rwlc)²

79-year-old man with laBCC who had discontinued prior vismodegib due to disease progression^{2*}



Individual patient responses may vary.
 This is an example from the **25%** of patients with laBCC who had a **PR** in Study 1620.¹



Actual clinical trial patient.

Clinical outcomes (as of data cutoff May 20, 2021)²

- **Best overall response:** PR by composite evaluation (RECIST 1.1 + WHO Criteria) per ICR
- **Time to response:** 4.2 months
- **Duration of response (DOR):** 32.36+ months

The ORR in Study 1620 was 32% in patients with laBCC and median DOR was not reached (range, 2.1-36.8+ months).¹

Plus sign (+) denotes ongoing at last assessment.¹
 *Patient received LIBTAYO 350 mg every 3 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.¹

Important Safety Information (continued)
Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)
Immune-mediated dermatologic adverse reactions (continued): Of the 17 patients in whom LIBTAYO was withheld for dermatologic adverse reaction, 13 reinitiated LIBTAYO after symptom improvement; of these, 5/13 (38%) had recurrence of the dermatologic adverse reaction. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes.
Other immune-mediated adverse reactions: The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% in 1281 patients who received LIBTAYO or were reported with the use of other PD-1/PD-L1-blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.

- **Cardiac/vascular:** Myocarditis, pericarditis, and vasculitis. Permanently discontinue for Grades 2, 3, or 4 myocarditis
- **Nervous system:** Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, and autoimmune neuropathy.


Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

In a study of patients with laBCC previously treated with an HHI,
Clinically meaningful tumor reduction observed after treatment with LIBTAYO²

66-year-old man with laBCC who had discontinued prior vismodegib due to intolerance^{2*}



Individual patient responses may vary.
 This is an example from the **25%** of patients with laBCC who had a **PR** in Study 1620.¹



Actual clinical trial patient.

Clinical outcomes (as of data cutoff May 20, 2021)²

- **Best overall response:** PR by composite evaluation (RECIST 1.1 + WHO Criteria) per ICR
- **Time to response:** 2.1 months
- **Duration of response:** 29.93+ months

The ORR in Study 1620 was 32% in patients with laBCC and median DOR was not reached (range, 2.1-36.8+ months).¹

Plus sign (+) denotes ongoing at last assessment.¹
 *Patient received LIBTAYO 350 mg every 3 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.¹

Important Safety Information (continued)
Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)
Other immune-mediated adverse reactions (continued):

- **Ocular:** Uveitis, iritis, and other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss
- **Gastrointestinal:** Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis, stomatitis

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



In a study of patients with laBCC previously treated with an HHI,
Clinically meaningful tumor reduction observed after treatment with LIBTAYO® (cemiplimab-rwlc)²


77-year-old woman with laBCC who discontinued prior vismodegib due to disease progression^{2*}

Right Nasal Cavity Lesion



Individual patient responses may vary.
This is an example from the **25%** of patients with laBCC who had a **PR** in Study 1620.¹

The duration of response for this patient was 4.8 months.
At the time of data cutoff, this patient was no longer in response due to having progressive disease.²



Actual clinical trial patient.

Clinical outcomes (as of data cutoff May 20, 2021)²

- **Best overall response:** PR by composite evaluations (RECIST 1.1 + WHO Criteria) per ICR
- **Time to response:** 8.2 months
- **Duration of response:** 4.8 months

The ORR in Study 1620 was 32% in patients with laBCC and median DOR was not reached (range, 2.1–36.8+ months).¹

Plus sign (+) denotes ongoing at last assessment.¹

*Patient received LIBTAYO 350 mg every 3 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.¹


In a study of patients with laBCC previously treated with an HHI,
Clinically meaningful tumor reduction observed after treatment with LIBTAYO²

49-year-old man with laBCC who discontinued prior vismodegib due to disease progression^{2*}

Left Periorbital Lesion



Individual patient responses may vary.
This is an example from the **7%** of patients with laBCC who had a **CR** in Study 1620.¹



Actual clinical trial patient.

Clinical outcomes (as of data cutoff May 20, 2021)²

- **Best overall response:** CR by composite evaluation (RECIST 1.1 + WHO Criteria) per ICR
- **Time to response:** 4.2 months
- **Duration of response:** 23.82+ months

The ORR in Study 1620 was 32% in patients with laBCC and median DOR was not reached (range, 2.1–36.8+ months).¹

Plus sign (+) denotes ongoing at last assessment.¹

*Patient received LIBTAYO 350 mg every 3 weeks. Please refer to the study design for the recommended dosage of LIBTAYO.¹

Important Safety Information (continued)

Warnings and Precautions (continued)

Severe and Fatal Immune-Mediated Adverse Reactions (continued)

Other immune-mediated adverse reactions (continued):

- **Musculoskeletal and connective tissue:** Myositis/polymyositis/dermatomyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica
- **Endocrine:** Hypoparathyroidism
- **Other (hematologic/immune):** Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).

Important Safety Information (continued)

Warnings and Precautions (continued)

Infusion-Related Reactions

Severe or life-threatening infusion-related reactions occurred in 0.2% of patients receiving LIBTAYO as a single agent. Monitor patients for signs and symptoms of infusion-related reactions. Common symptoms of infusion-related reaction include nausea, pyrexia, and vomiting. Interrupt or slow the rate of infusion or permanently discontinue LIBTAYO based on severity of reaction.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).



LIBTAYO® (cemiplimab-rwlc) demonstrated a favorable safety profile in Study 1620¹

ARs in ≥10% of patients	LIBTAYO (N=138)	
	All Grades, %	Grades 3–4, %
General disorders and administration site conditions		
Fatigue*	50	4.3
Edema [†]	10	0.7
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain [‡]	36	2.9
Gastrointestinal disorders		
Diarrhea [§]	33	4.3
Nausea	13	0.7
Abdominal pain	12	1.4
Constipation	12	0.7
Skin and subcutaneous tissue disorders		
Rash [¶]	30	0.7
Pruritus	19	0
Infections and infestations		
Upper respiratory tract infection [#]	22	0
Urinary tract infection ^{**}	13	2.2
Vascular disorders		
Hemorrhage ^{††}	18	0.7
Hypertension ^{‡‡}	17	9
Metabolism and nutrition disorders		
Decreased appetite	14	1.4
Blood and lymphatic system disorders		
Anemia	14	0.7
Respiratory, thoracic, and mediastinal disorders		
Dyspnea ^{§§}	14	0
Renal and urinary disorders		
Acute kidney injury	14	0
Nervous system disorders		
Headache	13	1.4
Dizziness ^{¶¶}	12	0
Peripheral neuropathy ^{###}	11	0
Endocrine disorders		
Hypothyroidism ^{***}	12	0
Investigations		
Liver function test abnormalities ^{†††}	10	1.4

Toxicity was graded per NCI CTCAE v.4.03.¹

*Fatigue is a composite term that includes fatigue, asthenia, and malaise.¹

[†]Edema is a composite term that includes peripheral edema, peripheral swelling, and face swelling.¹

[‡]Musculoskeletal pain is a composite term that includes arthralgia, back pain, pain in extremity, myalgia, neck pain, non-cardiac chest pain, arthritis, musculoskeletal chest pain, musculoskeletal stiffness, musculoskeletal discomfort, and spinal pain.¹

[§]Diarrhea is a composite term that includes diarrhea, colitis, autoimmune colitis, and enterocolitis.¹

^{||}Abdominal pain is a composite term that includes abdominal pain, abdominal pain upper, abdominal pain lower, and gastrointestinal pain.¹

[¶]Rash is a composite term that includes rash maculopapular, eczema, rash, dermatitis, erythema, dermatitis acneiform, rash pruritic, rash pustular, dermatitis bullous, dyshidrotic eczema, pemphigoid, rash erythematous, urticaria, nodular rash, and skin exfoliation.¹

[#]Upper respiratory tract infection is a composite term that includes upper respiratory tract infection, influenza like illness, nasopharyngitis, rhinitis, sinusitis, viral rhinitis, pharyngitis, laryngitis, respiratory tract infection, influenza, viral upper respiratory tract infection, and influenza A virus test positive.¹

^{**}Urinary tract infection is a composite term that includes urinary tract infection, cystitis, and urosepsis.¹

^{††}Hemorrhage is a composite term that includes tumor hemorrhage, hematuria, epistaxis, eye hemorrhage, hemoptysis, hemorrhage intracranial, hemorrhagic diathesis, postmenopausal hemorrhage, rectal hemorrhage, skin hemorrhage, skin neoplasm bleeding, ulcer hemorrhage, vaginal hemorrhage, wound hemorrhage, and subcutaneous hematoma.¹

^{‡‡}Hypertension is a composite term that includes hypertension, blood pressure increased, and hypertensive crisis.¹

^{§§}Dyspnea is a composite term that includes dyspnea and dyspnea exertional.¹

^{|||}Acute kidney injury is a composite term that includes blood creatinine increased, acute kidney injury, renal failure, renal impairment, glomerular filtration rate decreased, and nephropathy toxic.¹

^{¶¶}Dizziness is a composite term that includes dizziness and vertigo.¹

^{###}Peripheral neuropathy is a composite term that includes paresthesia, dysesthesia, hypoesthesia, peripheral motor neuropathy, burning sensation, neuralgia, and peripheral sensory neuropathy.¹

^{***}Hypothyroidism is a composite term that includes hypothyroidism, blood thyroid stimulating hormone increased, and immune-mediated hypothyroidism.¹

^{†††}Liver function test abnormalities is a composite term that includes alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood alkaline phosphatase increased, blood bilirubin increased, and gamma-glutamyl transferase increased.¹

Grade 3–4 laboratory abnormalities in Study 1620¹

Laboratory abnormalities in ≥1% of patients	LIBTAYO (N=138)
	Grades 3–4, %*
Hematology	
Lymphopenia	2.9
Electrolytes	
Hyponatremia	2.9
Hypokalemia	1.5
Coagulation	
Activated partial thromboplastin time prolonged	1.9

- The most common ARs reported in at least 15% of patients were fatigue, musculoskeletal pain, diarrhea, rash, upper respiratory tract infection, pruritus, hemorrhage, and hypertension¹
- The most common Grade 3 or 4 ARs (>2%) were hypertension, diarrhea, fatigue, musculoskeletal pain, hypokalemia, hyponatremia, pneumonia, urinary tract infection, visual impairment, and weight decreased¹
- The most common (>2%) laboratory abnormalities worsening from baseline to Grade 3 or 4 were lymphopenia and hyponatremia¹
- Serious ARs occurred in 34% of patients. Serious ARs that occurred in >1.5% were diarrhea (3.6%), urinary tract infection (3.6%), pneumonia (2.9%), and hemorrhage (2.2%)¹
- Fatal ARs occurred in 4.3% of patients who received LIBTAYO, including acute kidney injury (0.7%) and cachexia worsening due to colitis (0.7%)¹
- Permanent discontinuation of LIBTAYO due to an AR occurred in 14% of patients. ARs resulting in permanent discontinuation of LIBTAYO in at least 2 patients were diarrhea, acute kidney injury, general physical health deterioration, and hepatitis¹
- Dosage interruptions of LIBTAYO due to an AR occurred in 40% of patients. ARs which required dosage interruptions in >2% of patients included diarrhea, musculoskeletal pain, acute kidney injury, fatigue, fall, headache, infusion-related reaction, hemorrhage, pneumonitis, upper respiratory tract infection, and urinary tract infection¹

Toxicity graded per NCI CTCAE v.4.03.¹

*Percentages are based on the number of patients with at least 1 postbaseline value available for that parameter.¹

Important Safety Information (continued)
Warnings and Precautions (continued)
Complications of Allogeneic HSCT

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1-blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1-blocking antibody prior to or after an allogeneic HSCT.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

Warnings and Precautions for LIBTAYO¹

Warnings and Precautions for LIBTAYO include severe and fatal immune-mediated adverse reactions such as immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic HSCT; and embryo-fetal toxicity. Monitor for symptoms and signs of immune-mediated adverse reactions.

For more information on Warnings and Precautions, see additional Important Safety Information throughout and in Section 5 of the accompanying full Prescribing Information.



Immune-mediated adverse reactions on therapy with LIBTAYO® (cemiplimab-rwlc)^{1*}

The safety of LIBTAYO was evaluated in 1281 patients with advanced solid malignancies¹

Immune-mediated adverse reactions (imARs)		ARs, % (N=1281)*					Led to permanent treatment discontinuation, %	Led to treatment withholding, %	Required systemic corticosteroids, %	Adverse reactions resolved, %
		All Grades, %	Grade 2, %	Grade 3, %	Grade 4, %	Fatal, %				
	Pneumonitis	2.6	1.6	0.6	0.3	NR	1.3	1.4	100	61
	Colitis	2.0	0.9	0.8	NR	NR	0.4	1.2	100	56
	Hepatitis	2.4	0.2	1.6	0.3	<0.1	1.4	0.7	100 [†]	39
	Endocrinopathies									
	Adrenal insufficiency	0.5	NR	0.5	NR	NR	<0.1	<0.1	83	17
	Hypophysitis [‡]	0.5	0.3	0.2	NR	NR	<0.1	0.2	86	14
	Thyroiditis [§]	0.6	0.3	NR	NR	NR	0	<0.1	0	13
	Hyperthyroidism	3.0	0.9	<0.1	NR	NR	0	0.5	8	56
	Hypothyroidism	7	6	<0.1	NR	NR	0.2	0.7	1.1	6
	Type 1 diabetes mellitus [¶]	<0.1	NR	NR	<0.1	NR	0	0.1	NR	NR
	Nephritis with renal dysfunction	0.7	0.5	<0.1	NR	<0.1	0.2	0.4	100	78
	Dermatologic [#]	1.9	0.8	0.9	NR	NR	0.2	1.3	100	71

*Important imARs listed here may not include all possible severe and fatal immune-mediated reactions.¹
[†]Four patients required additional immunosuppression with mycophenolate.¹
[‡]Can cause hypopituitarism.¹
[§]Blood thyroid stimulating hormone increased and blood thyroid stimulating hormone decreased have also been reported.¹
^{||}Majority of patients required long-term thyroid hormone replacement.¹
[¶]Can present with diabetic ketoacidosis.¹
[#]Exfoliative dermatitis, including SJS, TEN, and DRESS, has occurred with PD-1/PD-L1–blocking antibodies.¹
NR=Not reported in the USPI. Does not necessarily mean the value is 0 and may have occurred in a small percentage of patients.
DRESS=drug rash with eosinophilia and systemic symptoms; SJS=Stevens–Johnson syndrome; TEN=toxic epidermal necrolysis.








Important Safety Information (continued) Warnings and Precautions (continued)

Embryo–Fetal Toxicity

LIBTAYO can cause fetal harm when administered to a pregnant woman due to an increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LIBTAYO and for at least 4 months after the last dose.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).

Immune-mediated adverse reactions on therapy with LIBTAYO^{1*}

Other imARs		ARs, % (N=1281)*
		All Grades, %
	Cardiac/vascular [†]	<1
	Nervous system [‡]	<1
	Ocular [§]	<1
	Gastrointestinal	<1
	Musculoskeletal and connective tissue [¶]	<1
	Endocrine [#]	<1
	Hematologic/immune ^{**}	<1

*These imARs occurred in patients who received LIBTAYO or were reported with the use of other PD-1/PD-L1–blocking antibodies. Severe or fatal cases have been reported for some of these ARs.¹
[†]Includes myocarditis, pericarditis, and vasculitis.¹
[‡]Includes meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain–Barré syndrome, nerve paresis, and autoimmune neuropathy.¹
[§]Includes uveitis, iritis, and other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other imARs, consider a Vogt–Koyanagi–Harada–like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.¹
^{||}Includes pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis, and stomatitis.¹
[¶]Includes myositis/polymyositis/dermatomyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, and polymyalgia rheumatica.¹
[#]Includes hypoparathyroidism.¹
^{**}Includes hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, and solid organ transplant rejection.¹

Important Safety Information (continued) Adverse Reactions


LIBTAYO as a single agent: the most common adverse reactions (≥15%) are fatigue, musculoskeletal pain, rash, diarrhea, and anemia

LIBTAYO in combination with platinum-based chemotherapy: the most common adverse reactions (≥15%) are alopecia, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).



LIBTAYO® (cemiplimab-rwlc) has straightforward dosing¹



IV=intravenous.

Important Safety Information (continued)

Use in Specific Populations

- **Lactation:** Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO
- **Females and males of reproductive potential:** Verify pregnancy status in females of reproductive potential prior to initiating LIBTAYO

Please see accompanying full Prescribing Information.

LIBTAYO Surround® can help support patients throughout their treatment journey*

Visit LIBTAYOSurround.com to learn more.

Financial support[†]
Support that facilitates access to medication when eligible patients need assistance with out-of-pocket costs. LIBTAYO Surround will help investigate your patients' eligibility in the following programs:

- Commercial Copay Program[‡]
- Patient Assistance Program

Access and reimbursement support
Support to help your patients receive their medication as quickly as possible, including:

- Benefits investigation
- Prior authorization (PA) support to review and explain payer requirements
- Appeal assistance if PA is denied
- Claims assistance to address questions as you prepare claims and to review the status of claims with your patient's health insurer
- Product support in connection with product ordering

Additional LIBTAYO Surround support
Once patients are prescribed LIBTAYO, they have access to our dedicated Patient Navigators. Patient Navigators are available to complement the support provided by patients' healthcare providers.

Billing and coding

- NDC: 61755-008-01 or 61755-0008-0[§] (350 mg/7 mL)
- J-code: J9119 Injection, cemiplimab-rwlc, 1 mg

Effective July 1, 2023, the JZ modifier is required for reporting there was no discarded drug.

For more information, call **1.877.LIBTAYO (1.877.542.8296)**, select **option 1**, Monday–Friday, 8:00 AM–8:00 PM Eastern Time.

*LIBTAYO Surround provides access and reimbursement support to help your patients receive their medication as quickly as possible. Upon receipt of a LIBTAYO Surround Enrollment Form, a LIBTAYO Surround Reimbursement Specialist may be able to provide several types of assistance.

[†]Patients who are uninsured, underinsured, or lack coverage may be eligible to receive LIBTAYO at no cost. LIBTAYO Surround can help evaluate patients' eligibility for assistance.

[‡]Subject to annual maximum copay assistance amount of \$25,000. This program is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, Veterans Affairs/Department of Defense, TRICARE, or similar federal or state programs. Not a debit card program. The program does not cover or provide support for supplies, procedures, or any physician-related service associated with LIBTAYO. General non-product-specific copays, coinsurance, or insurance deductibles are not covered. This program only applies to patients who are at least 18 years of age, residents of the United States or its territories or possessions, are prescribed LIBTAYO (cemiplimab-rwlc) for an FDA-approved indication, and are insured by a commercial health plan that requires a copayment, coinsurance, and/or deductible amount for LIBTAYO. It is not an insurance benefit. LIBTAYO Surround reserves the right to rescind, terminate, or amend this offer, eligibility, and terms and conditions at any time without notice. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. This offer is not conditioned on any past, present, or future purchase, including refills. This offer is non-transferable, limited to one per person, and cannot be combined with any other offer or discount. This program is not valid where prohibited by law, taxed, or restricted. Offer has no cash value. Patients are responsible for any out-of-pocket costs for LIBTAYO that exceed the program assistance limit of \$25,000 per year. Program is not valid for cash-paying customers. Additional program conditions may apply.

[§]11-digit version of NDC code.



References

1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc. **2.** Data on file. Regeneron Pharmaceuticals, Inc. **3.** Study of REGN2810 (Anti-PD-1) in Patients with Advanced Malignancies. Accessed August 8, 2024. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT02383212> **4.** Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. *Am Soc Clin Oncol Educ Book*. 2020;40:398–407. **5.** Steenrod AW, Smyth EN, Bush EN, et al. A qualitative comparison of symptoms and impact of varying stages of basal cell carcinoma. *Dermatol Ther (Heidelb)*. 2015;5(3):183–199. **6.** Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med*. 2018;379(4):341–351. **7.** Have you heard of cutaneous squamous cell carcinoma? Skin Cancer Foundation. Updated September 27, 2023. Accessed August 8, 2024. <https://www.skincancer.org/blog/have-you-heard-of-cutaneous-squamous-cell-carcinoma/> **8.** Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. *J Am Acad Dermatol*. 2019;80(2):303–317. **9.** Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. *JAMA Dermatol*. 2015;151(9):976–981. **10.** Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattlinger AB. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. *Arch Facial Plast Surg*. 2006;8(5):314–318. **11.** Berens AM, Akkina SR, Patel SA. Complications in facial Mohs defect reconstruction. *Curr Opin Otolaryngol Head Neck Surg*. 2017;25(4):258–264. **12.** Harwood CA, Proby CM, Inman GJ, Leigh IM. The promise of genomics and the development of targeted therapies for cutaneous squamous cell carcinoma. *Acta Derm Venereol*. 2016;96(1):1–16. **13.** Kauvar AN, Arpey CJ, Hruza G, Olbrich SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. [published correction appears in *Dermatol Surg*. 2016 Mar;42(3):443. Mahmoud, Bassel H [added]]. *Dermatol Surg*. 2015;41(11):1214–1240. **14.** Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. *Am J Clin Dermatol*. 2016;17(5):491–508. **15.** Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JS. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. *J Multidisc Healthc*. 2018;11:49–61. **16.** Alam M, Armstrong A, Baum C, et al; Work Group, Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 2018;78(3):560–578. **17.** Bichakjian C, Armstrong A, Baum C, et al. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol*. 2018;78(3):540–559. **18.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 26, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. **19.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Basal Cell Skin Cancer V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed August 26, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. **20.** Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. *Eur J Cancer*. 2023;192:113254. doi:10.1016/j.ejca.2023.113254 **21.** Moreno-Ramírez D, Silva-Clavería F, Fernández-Orland A, Eiris N, Ruiz de Casas A, Ferrándiz L. Surgery for cutaneous squamous cell carcinoma and its limits in advanced disease. *Dermatol Pract Concept*. 2021;11(suppl 2):e2021167S. doi:10.5826/dpc.11S2a167S **22.** Muto P, Pastore F. Radiotherapy in the adjuvant and advanced setting of CSCC. *Dermatol Pract Concept*. 2021;11(suppl 2):e2021168S. doi:10.5826/dpc.11S2a168S **23.** Cartee TV, Alam M, Armbrrecht ES, et al. Patient-centered outcomes for skin cancer management: utilization of a patient Delphi process to identify important treatment themes. *Dermatol Surg*. 2019;45(2):246–253. **24.** Potenza C, Bernardini N, Balduzzi V, et al. A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma. *Biomed Res Int*. 2018;2018:9489163. doi:10.1155/2018/9489163 **25.** Chen C-I, Jalbert JJ, Wu N, Ruiz ES. Patterns of major cutaneous surgeries and reconstructions in patients with cutaneous squamous cell carcinoma in the USA. *Future Oncol*. 2024;20(11):691–701. **26.** Jalbert J, Chen C-I, Wu N, Fury M, Ge W, Ruiz E. Patterns of hedgehog inhibitor (HHI) treatment interruptions and reinitiations among patients with basal cell carcinoma (BCC) in real-world clinical practice. *J Clin Oncol*. 2020;38:15_suppl. Abstract e19349. doi:10.1200/JCO.2020.38.15_suppl.e19349 **27.** Dessinioti C, Plaka M, Soura E, et al. A practical guide for the follow-up of patients with advanced basal cell carcinoma during treatment with hedgehog pathway inhibitors. *Oncologist*. 2019;24(8):e755–e764. doi:10.1634/theoncologist.2018-0924 **28.** Yang X, Dinehart S. Practical tips for managing hedgehog pathway inhibitor side effects. *Practical Dermatology*. January 2017:32–38. **29.** Ge W, Chen CI, Wu N, Fury MG, Ruiz E, Jalbert JJ. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. *Future Oncol*. 2022;18(23):2561–2572. **30.** Svoboda SA, Johnson NM, Phillips MA. Systemic targeted treatments for basal cell carcinoma. *Cutis*. 2022;109(6):E25–E31. doi:10.12788/cutis.0560 **31.** Konidaris G, Rofail D, Randall J, et al. Qualitative patient interviews to characterize the human burden of advanced basal cell carcinoma following hedgehog pathway inhibitor treatment. *Dermatol Ther (Heidelb)*. 2023;13(8):1747–1761. **32.** Lear JT, Dummer R, Guminski A. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. *Oncotarget*. 2021;12(26):2531–2540. **33.** Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. *J Eur Acad Dermatol Venereol*. 2018;32(2):372–381. **34.** Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Switching hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. *Oncotarget*. 2021;12(20):2089–2100. **35.** Cowey L, Chen CI, Aguilar KM, et al. Real-world treatment patterns and outcomes among patients

References (continued)

with basal cell carcinoma following first-line hedgehog inhibitor discontinuation. *Dermatol Ther (Heidelb)*. 2022;12(5):1211–1224. **36.** Ascierto PA, Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. *J Immunother Cancer*. 2022;10(12):e005082. doi:10.1136/jitc-2022-005082 **37.** Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2024. **38.** Foote MC, McGrath M, Guminski A, et al. Phase II study of a single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. *Ann Oncol*. 2014;25(10):2047–2052. **39.** William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. *J Am Acad Dermatol*. 2017;77(6):1110–1113.e2. doi:10.1016/j.jaad.2017.07.048 **40.** Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2013;85(5):1275–1281. **41.** Jenni D, Karpova MB, Mühleisen B, et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. *ESMO Open*. 2016;1(1):e000003:1–7. doi:10.1136/esmoopen-2015-000003 **42.** Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. *Clin Cancer Res*. 2012;18(5):1435–1446. **43.** Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. *Cancer*. 1990;66(8):1692–1696. **44.** Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. *J Clin Oncol*. 2002;20(2):364–370. **45.** Maubec E, Petrow P, Scheer-Senryarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. *J Clin Oncol*. 2011;29(25):3419–3426. **46.** Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program; May 29–31, 2020. **47.** Migden MR, Schmults CD, Khushalani NI, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 Groups 1, 2 and 3. Poster presented at: European Society of Medical Oncology (ESMO) 2022 Annual Meeting; September 9–13, 2022; Paris, France. **48.** Rischin D, Lim AM, Schmults CD, et al. Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). Poster presented at: 2019 European Society for Medical Oncology Annual Meeting; September 27–October 1, 2019; Barcelona, Spain. **49.** Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months. Poster presented at: 10th World Congress of Melanoma in conjunction with 17th European Association of Dermato-Oncology (EADO) Congress 2021 Virtual Scientific Meeting; April 15–17, 2021. **50.** Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. *Lancet Oncol*. 2020;21(2):294–305. **51.** Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. *J Immunother Cancer*. 2021;9(8):e002757. doi:10.1136/jitc-2021-002757

EVIDENCE THAT EMPOWERS CHANGE

Empowering decision-making in patients with advanced CSCC and advanced BCC

ADVANCED CSCC: LIBTAYO is the **FIRST** treatment indicated for patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.¹

ADVANCED BCC: LIBTAYO is the **FIRST AND ONLY** treatment indicated for patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.¹

NCCN Guidelines recommend cemiplimab-rwlc (LIBTAYO) for systemic therapy*

- **Preferred category 2A** option for patients with advanced CSCC when curative surgery and curative radiation therapy are not feasible¹⁸
- **Recommended category 2A** option for patients with advanced BCC who were previously treated with an HHI or for whom an HHI is not appropriate¹⁹

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.

NCCN=National Comprehensive Cancer Network® (NCCN®).

NCCN is a registered trademark of the National Comprehensive Cancer Network® (NCCN®).

*Category 2A recommendation is based upon lower-level evidence; there is uniform NCCN consensus that the intervention is appropriate. All recommendations are Category 2A unless otherwise specified.^{18,19}

Validated in the **largest clinical trial program** for a PD-1 inhibitor in advanced CSCC and advanced BCC^{1,37-45}

>20k patients treated with LIBTAYO across all indications^{2†‡}

#1 most-prescribed IO by oncologists across both advanced CSCC and advanced BCC^{2‡}

>8 years of clinical treatment experience^{3§}

¹Since its first approval in 2018.¹

[†]Estimate based on IQVIA medical claims data from October 2018 through May 2023 and calibrated with actual vials sold.²

[§]FDA approved in advanced CSCC in 2018. Includes clinical trial experience and postmarketing data.^{1,3}



Scan to download
a copy of this brochure

Warnings and Precautions for LIBTAYO¹

Warnings and Precautions for LIBTAYO include severe and fatal immune-mediated adverse reactions such as immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic HSCT; and embryo-fetal toxicity. Monitor for symptoms and signs of immune-mediated adverse reactions.

For more information on Warnings and Precautions, see additional Important Safety Information throughout and in Section 5 of the accompanying full Prescribing Information.

REGENERON®

© 2024 Regeneron Pharmaceuticals, Inc. All rights reserved.
US.LIB.24.07.0022 08/24

 **LIBTAYO®**
(cemiplimab-rwlc)
Injection 350 mg